Clinical Advances in
New biologics with a novel mechanism of action offer new options for patients with inflammatory bowel disease (IBD) not optimally controlled with anti-tumor necrosis factor (TNF) agents. Integration of biologics into clinical practice together with emerging strategies for management of IBD -- including early intervention, new treatment goals, and personalized care -- will allow physicians to improve patient outcomes and potentially alter the progressive course of IBD.
Supported by an independent educational grant from
Steering Committee Chair
Gastroenterologist
Guy's and St Thomas' Hospital
London, United Kingdom
Professor
Humanitas University
Rozzano, Italy
Professor of Practice
St. Mark's Hospital
Department of Surgery and Cancer
Imperial College
London, UK
Professor
Academic Medical Center
Amsterdam, The Netherlands
Professor of Medicine
Department of Gastroenterology and Hepatology
University Hospital of Zürich
University of Zürich
Zurich, Switzerland
Professor of Medicine
Department of Internal Medicine I
Kiel University
Kiel, Germany